Il y a eu 50 transactions d'initiés récentes enregistrées pour POINT Biopharma Global Inc. (PNT), dont 25 achats et 21 ventes. Le total des achats d'initiés s'élève à $14.9M et le total des ventes d'initiés à $70.58M.
Les initiés notables ayant une activité récente comprennent Silber Allan C, Lubner David Charles, Malik Rajesh. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — PNT
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2023-12-27 |
Silber Allan C |
Executive Chairman |
Restitution d'Actions |
537,322 |
$6.78 |
$3.64M |
- |
| 2023-12-27 |
Lubner David Charles |
Director |
Restitution d'Actions |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Malik Rajesh |
Director |
Restitution d'Actions |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Fleshner Neil E. |
Chief Medical Officer |
Restitution d'Actions |
84,257 |
$6.78 |
$571.26K |
- |
| 2023-12-27 |
Demers William L. |
Chief Financial Officer |
Restitution d'Actions |
131,355 |
$6.78 |
$890.59K |
- |
| 2023-12-27 |
Goodman Jonathan R. |
Director |
Restitution d'Actions |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Margolin Yael |
Director |
Restitution d'Actions |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Mccann Joe A. |
Chief Executive Officer |
Restitution d'Actions |
692,643 |
$6.78 |
$4.7M |
- |
| 2023-12-27 |
Hogue Gerald L. |
Director |
Restitution d'Actions |
44,749 |
$9.12 |
$408.11K |
- |
| 2023-12-27 |
Jensen Jessica D. |
EVP Clinical Development |
Restitution d'Actions |
136,055 |
$6.78 |
$922.45K |
- |
| 2023-12-27 |
Kelly Justyna |
Chief Operating Officer |
Restitution d'Actions |
98,358 |
$6.78 |
$666.87K |
- |
| 2023-12-26 |
Lubner David Charles |
Director |
OPA (Vente) |
35,400 |
$12.50 |
$442.5K |
3,600 |
| 2023-12-26 |
Malik Rajesh |
Director |
OPA (Vente) |
3,700 |
$12.50 |
$46.25K |
- |
| 2023-12-26 |
Goodman Jonathan R. |
Director |
OPA (Vente) |
41,872 |
$12.50 |
$523.4K |
- |
| 2023-12-26 |
Hogue Gerald L. |
Director |
OPA (Vente) |
21,596 |
$12.50 |
$269.95K |
- |
| 2023-12-22 |
Silber Allan C |
Executive Chairman |
OPA (Vente) |
71,744 |
$12.50 |
$896.8K |
- |
| 2023-12-22 |
Fleshner Neil E. |
Chief Medical Officer |
OPA (Vente) |
358 |
$12.50 |
$4.48K |
- |
| 2023-12-22 |
Mccann Joe A. |
Chief Executive Officer |
OPA (Vente) |
3,494,153 |
$12.50 |
$43.68M |
- |
| 2023-12-18 |
Bvf Partners L P/il |
Officer |
Vente Informative |
896,366 |
$12.45 |
$11.16M |
- |
| 2023-11-06 |
Mccann Joe A. |
Chief Executive Officer |
Don (Donné) |
120,000 |
- |
- |
3,494,153 |
| 2023-11-03 |
Silber Allan C |
Executive Chairman |
Don (Donné) |
500,000 |
- |
- |
38,087 |
| 2023-11-02 |
Bvf Partners L P/il |
10 Percent Owner |
Cession |
- |
- |
- |
896,366 |
| 2023-10-31 |
Fleshner Neil E. |
Chief Medical Officer |
Don (Donné) |
250,000 |
- |
- |
2,773,045 |
| 2023-06-13 |
Martell Bridget A |
Director |
Attribution de RSU |
80,503 |
$10.08 |
$811.47K |
80,503 |
| 2023-06-12 |
Martell Bridget A |
Director |
Inconnu |
- |
- |
- |
- |
| 2023-06-01 |
Lubner David Charles |
Director |
Attribution de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Malik Rajesh |
Director |
Attribution de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Goodman Jonathan R. |
Director |
Attribution de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Margolin Yael |
Director |
Attribution de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-06-01 |
Hogue Gerald L. |
Director |
Attribution de RSU |
44,749 |
$9.12 |
$408.11K |
44,749 |
| 2023-03-28 |
Silber Allan C |
10 Percent Owner, Officer: Executive Chairman |
Attribution de RSU |
537,322 |
$6.78 |
$3.64M |
537,322 |
| 2023-03-28 |
Fleshner Neil E. |
Chief Medical Officer |
Attribution de RSU |
84,257 |
$6.78 |
$571.26K |
84,257 |
| 2023-03-28 |
Demers William L. |
Chief Financial Officer |
Attribution de RSU |
131,355 |
$6.78 |
$890.59K |
131,355 |
| 2023-03-28 |
Mccann Joe A. |
Chief Executive Officer |
Attribution de RSU |
692,643 |
$6.78 |
$4.7M |
692,643 |
| 2023-03-28 |
Jensen Jessica D. |
EVP Clinical Development |
Attribution de RSU |
136,055 |
$6.78 |
$922.45K |
136,055 |
| 2023-03-28 |
Kelly Justyna |
Chief Operating Officer |
Attribution de RSU |
98,358 |
$6.78 |
$666.87K |
98,358 |
| 2023-03-21 |
Hogue Gerald L. |
Director |
Exercice d'Options (Vente) |
17,936 |
$6.97 |
$125.01K |
17,936 |
| 2022-11-29 |
Mccann Joe A. |
Chief Executive Officer |
Achat Informatif |
2,160 |
$6.64 |
$14.34K |
3,616,313 |
| 2022-11-28 |
Malik Rajesh |
Director |
Achat Informatif |
3,700 |
$6.66 |
$24.64K |
3,700 |
| 2022-11-25 |
Hogue Gerald L. |
Director |
Achat Informatif |
3,660 |
$6.82 |
$24.94K |
3,660 |
| 2022-11-23 |
Lubner David Charles |
Director |
Achat Informatif |
3,600 |
$6.85 |
$24.66K |
3,600 |
| 2022-11-21 |
Margolin Yael |
Director |
Achat Informatif |
1,710 |
$6.56 |
$11.22K |
1,710 |
| 2022-11-18 |
Silber Allan C |
Executive Chairman |
Achat Informatif |
22,397 |
$6.50 |
$145.58K |
4,268,605 |
| 2022-11-18 |
Goodman Jonathan R. |
Director |
Achat Informatif |
6,000 |
$6.33 |
$37.98K |
41,872 |
| 2022-11-17 |
Silber Allan C |
Executive Chairman |
Achat Informatif |
27,603 |
$6.00 |
$165.62K |
4,246,208 |
| 2022-06-02 |
Lubner David Charles |
Director |
Attribution de RSU |
25,614 |
$8.31 |
$212.85K |
25,614 |
| 2022-06-02 |
Malik Rajesh |
Director |
Attribution de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Goodman Jonathan R. |
Director |
Attribution de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Margolin Yael |
Director |
Attribution de RSU |
25,614 |
- |
- |
25,614 |
| 2022-06-02 |
Hogue Gerald L. |
Director |
Attribution de RSU |
25,614 |
- |
- |
25,614 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
